Chembio Diagnostics Reports Fourth Quarter and Full Year 2017 Financial Results

- March 9th, 2018

Chembio Diagnostics (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: Achieved total revenue of $24.0 million of which net product sales were $19.3 million for the full year 2017, increases of 34% …

Chembio Diagnostics (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

  • Achieved total revenue of $24.0 million of which net product sales were $19.3 million for the full year 2017, increases of 34% and 41% respectively, over prior year
  • Received $8.5 million 2018 purchase commitment from Bio-Manguinhos in Brazil for DPP® HIV Assays and DPP® Leishmania Assays
  • Won three-year, $15.8 million total contract value tender from the Ethiopian Pharmaceuticals Fund and Supply Agency to deliver HIV STAT-PAK® Assays between 2018-2020
  • Received conditional award of $1.5 million to $4.9 million in 2018-2019 from UNICEF for DPP® Zika Systems

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Leave a Reply